Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation

In the long term, Gilead's (NASDAQ: GILD ) top and bottom lines should be meaningfully lifted by its lenacapavir drug which has been shown to prevent nearly all HIV transmission and could become a blockbuster for the firm. AndAnalyst’s Disclosure: I/we have a beneficial long position in the shares of GSK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have n ...